On Dec. 11, YY Inc. (NASDAQ:YY) announced that it has reached a definitive agreement to fully acquire Beijing Huanqiu Xingxue Technology Development Co., Ltd (“Xingxue”) and Beijing Huanqiu Chuangzhi Software Co., Ltd (“Chuangzhi”) from Shanghai Global Career Education Science & Technology Holding Company (“Huanqiu”) for a total cash consideration of approximately RMB 120 million. The transaction is subject to customary closing conditions. YY Inc. (NASDAQ:YY) in last trading activity increased 1.32% to close at $65.43. Company weekly performance is 1.68% while its quarterly performance stands at -13.84%. YY Inc. (NASDAQ:YY) is -32.12% away from its 52 week high.
Varonis Systems (NASDAQ:VRNS) major shareholder Iv L.P. Evergreen sold 83,269 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $25.19, for a total transaction of $2,097,546.11. On last trading day Varonis Systems, Inc. (NASDAQ:VRNS) increased 8.29% to close at $30.17. Its volatility for the week is 7.55% while volatility for the month is 5.63%. Varonis Systems, Inc. (NASDAQ:VRNS) monthly performance is 32.56%.
Old Republic International Corporation (NYSE:ORI ) begin trading ex-dividend on December 03, 2014. A cash dividend payment of $0.1825 per share is scheduled to be paid on December 15, 2014. On last trading day Old Republic International Corporation (NYSE:ORI) increased 0.42% to close at $14.42. Its volatility for the week is 1.89% while volatility for the month is 1.71%. ORI’s sales growth for past 5 years was 10.90% and its EPS growth for past 5 years was 21.50%. Old Republic International Corporation (NYSE:ORI) monthly performance is -1.77%.
Precision Drilling Corp (NYSE:PDS) has been given an average recommendation of “Buy” by the fifteen analysts that are presently covering the company, American Banking and Market News reports. Precision Drilling Corporation (NYSE:PDS) has 3.45% insider ownership while its institutional ownership stands at 45.90%. In last trading activity company’s stock closed at $6.84.
On Dec. 19, Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba™ (naltrexone HCI / bupropion HCI prolonged release), as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to ˂ 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). On Friday shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) closed at $6.33. Company’s sales growth for last 5 years was 102.40% and EPS growth for next 5 years is recorded as 13.90%.